Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has recently improved its financial position through equity financings and option exercises, achieving a notable increase in financing income, which rose to $284K for the quarter and $611K year-to-date. The company has made significant strides in preparing for the full launch of its LIBERTY Endovascular Robotic System, including expanding its commercial capabilities and receiving positive feedback from healthcare providers, indicating strong market potential. As Microbot Medical positions itself for accelerated growth with upcoming product launches and has established critical partnerships to enhance operational readiness, its competitive market stance could justify a premium valuation as it approaches key milestones.

Bears say

Microbot Medical Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to delayed commercialization of its LIBERTY Endovascular Robotic System and slower-than-expected market acceptance. The company also encounters risks relating to its inability to expand into neuro and cardio cases, setbacks in securing international regulatory approvals, and persistent reimbursement headwinds, all of which may hinder its growth potential. Moreover, the lack of profitability in the near term and the erosion of hospital margins due to the cost of its device further amplify concerns about the company’s financial sustainability.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.